High-Throughput Surveillance Study on Antibiotic Resistance Using the Automated SmartChip™ System

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is
proud to announce that researchers at the University of Helsinki,
Universidade Católica Portuguesa, CBQF, and Technische Universität
Dresden, Institute of Hydrobiology, along with other collaborators have
performed the first
trans-Europe surveillance study on antibiotic resistance utilizing
the SmartChip
Real-Time PCR System.

This high-throughput study gathered data covering a large number of
antibiotic resistance genes (ARGs) from a dozen wastewater plants across
seven European countries. The SmartChip system enabled efficient,
sensitive qPCR on three technical replicates of nearly 300 different
ARGs. While temperature and size of the wastewater plant were noted as
important factors, analysis of the data identified a pattern of
antibiotic resistance that was strongly correlated with antibiotic use.
These results demonstrate the need for regular surveillance and
implementation of control measures on a global scale.

“It is extremely gratifying to see researchers make headway on such an
important topic by taking advantage of the large-scale, flexible
capabilities of the SmartChip system,” said Carol Lou, President of
Takara Bio USA, Inc. “High-throughput qPCR is a powerful tool for data
analysis related to a wide range of human health issues, including
pathogen detection, clinical biomarkers, and antibiotic resistance. We
are pleased to see this platform enabling advancements in these areas of
global concern.”

About Takara Bio USA, Inc.

Takara
Bio USA, Inc. (TBUSA; formerly Clontech Laboratories, Inc.) is a
wholly owned subsidiary of Takara
Bio Inc. that manufactures and distributes kits, reagents, and
instruments for life sciences research applications, including NGS, PCR,
gene delivery, genome editing, stem cell research, nucleic acid and
protein purification, and automated sample preparation.

Contacts

Lorna Neilson, Ph.D.
VP, Corporate Development
[email protected]
650.919.7372